Genetic Variants in the Hippo Pathway Predict Biochemical Recurrence After Radical Prostatectomy for Localized Prostate Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2015 Feb 25

PMID 25707771

Citations 17

Authors

Chao-Yuan Huang

Shu-Pin Huang

Victor C Lin

Chia-Cheng Yu

Ta-Yuan Chang

Shin-Hun Juang

Bo-Ying Bao

Affiliations

Soon will be listed here.

Abstract

While localized prostate cancer is potentially curative, many patients still show biochemical recurrence (BCR) after curative treatments such as radical prostatectomy (RP). The Hippo pathway has recently been shown to be an evolutionarily conserved regulator of tissue growth, and its perturbation can trigger tumorigenesis. We hypothesize that genetic variants of the Hippo pathway may influence clinical outcomes in localized prostate cancer patients. We genotyped 53 tagging single-nucleotide polymorphisms (SNPs) from seven core Hippo pathway genes in 246 localized prostate cancer patients treated with RP. Kaplan-Meier analysis and Cox proportional hazard models were utilized to identify significant SNPs that correlated with BCR. For replication, five associated SNPs were genotyped in an independent cohort of 212 patients. After adjusting for known clinicopathologic factors, the association between STK3 rs7827435 and BCR (P = 0.018) was replicated in the second stage (P = 0.026; Pcombined = 0.001). Additional integrated in silico analysis provided evidence that rs7827435 affects STK3 expression, which in turn is significantly correlated with tumor aggressiveness and patient prognosis. In conclusion, genetic variants of the Hippo pathway contribute to the variable outcomes of prostate cancer, and the discovery of these biomarkers provides a molecular approach for prognostic risk assessment.

Citing Articles

Interplay of Developmental Hippo-Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer.

Mourkioti I, Angelopoulou A, Belogiannis K, Lagopati N, Potamianos S, Kyrodimos E Cells. 2022; 11(15).

PMID: 35954292 PMC: 9367915. DOI: 10.3390/cells11152449.

TNFRSF13B is a potential contributor to prostate cancer.

Li C, Huang S, Chen Y, Wu H, Cheng W, Huang C Cancer Cell Int. 2022; 22(1):180.

PMID: 35524261 PMC: 9074181. DOI: 10.1186/s12935-022-02590-2.

Genetic variant located on chromosome 17p12 contributes to prostate cancer onset and biochemical recurrence.

Pavel A, Stambouli D, Gener I, Preda A, Anton G, Baston C Sci Rep. 2022; 12(1):4546.

PMID: 35296725 PMC: 8927158. DOI: 10.1038/s41598-022-08472-x.

Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia.

Bata N, Chaikuad A, Bakas N, Limpert A, Lambert L, Sheffler D J Med Chem. 2021; 65(2):1352-1369.

PMID: 34807584 PMC: 10149138. DOI: 10.1021/acs.jmedchem.1c00804.

Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer.

Schirmer A, Driver L, Zhao M, Wells C, Pickett J, OBryne S Mol Ther. 2021; 30(1):485-500.

PMID: 34450249 PMC: 8753456. DOI: 10.1016/j.ymthe.2021.08.029.

References

Tapon N, Harvey K, Bell D, Wahrer D, Schiripo T, Haber D . salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 2002; 110(4):467-78. DOI: 10.1016/s0092-8674(02)00824-3. View

. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013; 45(6):580-5. PMC: 4010069. DOI: 10.1038/ng.2653. View

Veltman J, Fridlyand J, Pejavar S, Olshen A, Korkola J, DeVries S . Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res. 2003; 63(11):2872-80. View

Sung V, Luo W, Qian D, Lee I, Jallal B, Gishizky M . The Ste20 kinase MST4 plays a role in prostate cancer progression. Cancer Res. 2003; 63(12):3356-63. View

Jia J, Zhang W, Wang B, Trinko R, Jiang J . The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev. 2003; 17(20):2514-9. PMC: 218145. DOI: 10.1101/gad.1134003. View

Cher M, Bova G, Moore D, Small E, Carroll P, Pin S . Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 1996; 56(13):3091-102. View

Nupponen N, Kakkola L, Koivisto P, Visakorpi T . Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol. 1998; 153(1):141-8. PMC: 1852946. DOI: 10.1016/S0002-9440(10)65554-X. View

ONeill E, Matallanas D, Kolch W . Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res. 2005; 65(13):5485-7. DOI: 10.1158/0008-5472.CAN-05-1453. View

Huang J, Wu S, Barrera J, Matthews K, Pan D . The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005; 122(3):421-34. DOI: 10.1016/j.cell.2005.06.007. View

10.

de Bakker P, Yelensky R, Peer I, Gabriel S, Daly M, Altshuler D . Efficiency and power in genetic association studies. Nat Genet. 2005; 37(11):1217-23. DOI: 10.1038/ng1669. View

11.

Edgar B . From cell structure to transcription: Hippo forges a new path. Cell. 2006; 124(2):267-73. DOI: 10.1016/j.cell.2006.01.005. View

12.

Saramaki O, Porkka K, Vessella R, Visakorpi T . Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer. 2006; 119(6):1322-9. DOI: 10.1002/ijc.21976. View

13.

Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford S . Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130(6):1120-33. PMC: 2666353. DOI: 10.1016/j.cell.2007.07.019. View

14.

Frazer K, Ballinger D, Cox D, Hinds D, Stuve L, Boudreau A . A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007; 449(7164):851-61. PMC: 2689609. DOI: 10.1038/nature06258. View

15.

Cinar B, Fang P, Lutchman M, Di Vizio D, Adam R, Pavlova N . The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J. 2007; 26(21):4523-34. PMC: 2063482. DOI: 10.1038/sj.emboj.7601872. View

16.

Zhao B, Wei X, Li W, Udan R, Yang Q, Kim J . Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007; 21(21):2747-61. PMC: 2045129. DOI: 10.1101/gad.1602907. View

17.

Shao Y, Demissie K, Shih W, Mehta A, Stein M, Roberts C . Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009; 101(18):1280-3. PMC: 2744729. DOI: 10.1093/jnci/djp262. View

18.

Yu K, DI G, Fan L, Shao Z . Test of Hardy-Weinberg equilibrium in breast cancer case-control studies: an issue may influence the conclusions. Breast Cancer Res Treat. 2009; 117(3):675-7. DOI: 10.1007/s10549-009-0353-x. View

19.

Xu M, Yao T, Lee N, Ng I, Chan Y, Zender L . Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009; 115(19):4576-85. PMC: 2811690. DOI: 10.1002/cncr.24495. View

20.

Huang S, Huang L, Ting W, Chen L, Chang T, Lu T . Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2009; 18(11):3068-74. DOI: 10.1158/1055-9965.EPI-09-0665. View